TheTechno Optimist.

StoryPartnership3 Jun 2026

Alnylam partners with Inceptive for AI-driven RNAi drug discovery

Alnylam Pharmaceuticals

Alnylam and Inceptive announced a $2B strategic collaboration to accelerate RNAi therapeutic discovery. The partnership combines Alnylam's established RNAi platform and decades of proprietary siRNA data with Inceptive's AI expertise and foundation models.

Read the original · Press Biotech

More on Alnylam Pharmaceuticals

Alnylam reports Q2 2026 revenue of $1.172 billion, with Amvuttra reaching $1.01 billion in quarterly revenue3 Aug 2026
Alnylam unveils 'Alnylam 2030' strategy to expand RNAi beyond rare disease into diabetes, obesity, and neurological disorders11 Jan 2026
FDA approves Amvuttra (vutrisiran) for transthyretin amyloid cardiomyopathy (ATTR-CM)Jun 2023